Berinert market seen expanding through 2030 on better diagnosis and access

The Business Research Company says the Berinert market is set for continued growth through 2030 as hereditary angioedema diagnosis improves, healthcare spending rises and more patients gain access to plasma-derived treatments. North America led the market in 2025, while Asia-Pacific is projected to grow the fastest.

Why it matters: - Berinert is a key treatment for hereditary angioedema, a rare genetic disorder that can trigger severe swelling, including airway attacks. - The market outlook matters because better diagnosis, wider treatment access and stronger healthcare systems can expand use of the therapy for patients at risk of life-threatening episodes.

What happened: - The Business Research Company published its Berinert Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Nov. 2, 2026. - The report says the Berinert market has grown steadily in recent years and is expected to keep expanding through 2030 and beyond. - North America held the largest share of the Berinert market in 2025. - Asia-Pacific is expected to post the fastest growth rate during the forecast period.

The details: - Berinert is a prescription drug made from human plasma and contains C1 esterase inhibitor. - The therapy replaces deficient or malfunctioning C1 esterase inhibitor in patients with hereditary angioedema. - The treatment helps regulate inflammation and blood vessel permeability through the complement and contact systems. - The report ties past market growth to identification of C1 esterase inhibitor deficiency, approval of plasma-derived HAE treatments, improved rare-disease diagnosis, greater use of specialist immunology services and increased awareness of emergency airway risks. - The report says future growth could come from better genetic screening for HAE, expansion of rare disease centers, more plasma fractionation capacity, patient access programs and more long-term safety data. - The report highlights rising diagnosis rates of hereditary angioedema, broader use of plasma-derived therapies, hospital-based management of acute HAE episodes, rapid on-demand treatment and more rare-disease awareness programs as key trends. - Increasing genetic disorders are a major market driver because better awareness and diagnostic technology are leading to earlier and more accurate detection. - In Australia, the National Blood Authority reported 2,788 patients with hereditary haemophilia A in 2023–2024, up from 2,681 the year before. - Rising healthcare expenditure is also supporting access to specialized C1 esterase inhibitor therapies. - The UK Office for National Statistics reported a 5.6% nominal rise in total healthcare expenditure in 2023, a 0.9% increase compared with 2022. - The report also points to an aging population as a demand driver because older patients may face more health challenges and need better management of acute swelling attacks. - The UK Parliament’s House of Commons Library said 12.7 million people in the UK were aged 65 or older in 2022, equal to 19% of the population. - That figure is expected to rise to 22.1 million, or 27%, by 2072. - The report covers Western Europe, Eastern Europe, South America, the Middle East and Africa in addition to North America and Asia-Pacific.

Between the lines: - The market thesis rests less on a single product launch and more on structural changes in rare-disease care, including better testing, stronger referral networks and improved access to specialty therapies. - A faster-growing Asia-Pacific market suggests the biggest upside may come from healthcare expansion and diagnosis improvements outside the most mature markets. - The report also signals that reimbursement, plasma supply and specialist infrastructure remain central to real-world adoption.

What's next: - The report expects continued gains as genetic screening expands and more patients are identified earlier. - Market growth will likely depend on whether healthcare systems can scale rare-disease centers, secure plasma-derived supply and support patient access programs. - The company says the 2026 report includes updated graphics, TAM analysis, company scoring matrices, forecasting dashboards and trend analysis.